Ipamorelin therapy complements this by gently stimulating the ghrelin receptor, creating balanced GH pulses that promote lean muscle gain, fat loss, and improved recovery
Sermorelin has a lower impact on blood sugar compared to direct HGH, but regular monitoring is still important
(5) Kopchick JJ, Berryman DE, Puri V, Lee KY, Jorgensen JOL
Peptide (Brand) Indication Route Key Features Sermorelin (Geref) Growth hormone deficiency SC GHRH analog Tesamorelin (Egrifta) HIV-associated lipodystrophy SC Reduces excess abdominal fat see full Tesamorelin FDA status guide or compare Tesamorelin 10mg research peptide availability Mecasermin (Increlex) Severe primary IGF-1 deficiency SC IGF-1 replacement Corticorelin (Acthrel) Pituitary-adrenal axis testing IV Diagnostic ACTH analog GI & Motility Peptides Linaclotide (Linzess/Constella): Guanylate cyclase-C agonist for IBS-C and chronic constipation (2012) Plecanatide (Trulance): Similar mechanism for CIC and IBS-C (2017) Lubiprostone (Amitiza): Chloride channel activator for CIC (2006) Cardiovascular & Vasoactive Peptides Angiotensin II (Giapreza): Vasoconstrictor for distributive shock (2017) Vasopressin (Vasostrict): Vasodilatory shock treatment (2014) Eptifibatide (Integrilin): GP IIb/IIIa inhibitor for ACS (1998) Bivalirudin (Angiomax): Anticoagulant for PCI (2000) Natural & Endogenous Peptides The FDA has approved approximately 10 natural peptide analogs that mimic endogenous hormones: Insulin (1923) The first approved peptide therapeutic Corticotropin/ACTH (1952) Multiple sclerosis and infantile spasms Oxytocin (1996) Uterine contraction and lactation support Glucagon (1998) Severe hypoglycemia rescue Secretin (2002) Diagnostic aid for pancreatic function Calcitonin (2005) Hypercalcemia and osteoporosis Oral vs Injectable FDA Approved Peptide Drugs Most FDA approved peptide drugs are injectable because peptide chains are usually broken down in the gastrointestinal tract before they can reach systemic circulation
In non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis, it was shown that the levels of GH, IGF-1, and IGFBP-3 varied according to the severity of the steatosis, which differed from the variation in samples taken from patients with hepatitis C virus-related CLD (239)
